Impact of ABO Blood Type on Outcomes in Patients with Primary Nonmuscle Invasive Bladder Cancer

Author:

Klatte Tobias1,Xylinas Evanguelos23,Rieken Malte2,Kluth Luis A.24,Rouprêt Morgan56,Pycha Armin7,Fajkovic Harun1,Seitz Christian1,Karakiewicz Pierre I.8,Lotan Yair9,Babjuk Marko10,de Martino Michela1,Scherr Douglas S.2,Shariat Shahrokh F.12

Affiliation:

1. Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria

2. Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York

3. Department of Urology, Cochin Hospital, Assistance Publique Hopitaux de Paris, Paris Descartes University, Paris, France

4. Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

5. Department of Urology, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique Hopitaux de Paris, Faculty of Medicine Pierre et Marie Curie, Institut Universitaire de Cancérologie GRC5, University Paris 6, Paris, France

6. Department of Urology, University Hospital Basel, Basel, Switzerland

7. Department of Urology, Central Hospital of Bolzano, Bolzano, Italy

8. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Quebec, Canada

9. Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas

10. Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Prague, Czech Republic

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference26 articles.

1. Cancer statistics, 2013;Siegel;CA Cancer J Clin,2013

2. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013;Babjuk;Eur Urol,2013

3. Clark PE, Agarwal N, Biagioli MC et al: National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Bladder Cancer, Version 1.2013. Available at http://nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed September 15, 2013.

4. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model;Fernandez-Gomez;J Urol,2009

5. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials;Sylvester;Eur Urol,2006

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3